Atherosclerosis in primary antiphospholipid syndrome

References

• Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4, 295–306 (2006).
   PubMed Web of Science ®Google Scholar
• Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum.56, 1384–1396 (2007).
   PubMedGoogle Scholar
• Alarcon-Segovia D, Cardiel MH, Reyes E. Antiphospholipid arterial vasculopathy. J. Rheumatol.16, 762–767 (1989).
   PubMed Web of Science ®Google Scholar
• Lie JT. Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? J. Rheumatol.16, 713–715 (1989).
   PubMed Web of Science ®Google Scholar
• Taylor LM Jr, Chitwood RW, Dalman RL, Sexton G, Goodnight SH, Porter JM. Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. Ann. Surg.220, 544–551 (1994).
   PubMedGoogle Scholar
• Lam EY, Taylor LM, Landry GJ, Porter JM, Moneta GL. Relationship between antiphospholipid antibodies and progression of lower extremity arterial occlusive disease after lower extremity by-pass operations. J. Vasc. Surg33, 976–982 (2001).
   PubMedGoogle Scholar
• Nityanand S, Bergmark C, de Faire U, Swedenborg J, Holm G, Lefvert AK. Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J. Intern. Med.238, 437–443 (1995).
   PubMed Web of Science ®Google Scholar
• Friehs I, Eber B, Friehs G, Langsteger W, Koch G. IgG-anticardiolipin-antibodies are markers for cerebral and peripheral artery disease. Vasa21, 158–162 (1992).
   PubMedGoogle Scholar
• Fligelstone LJ, Cachia PG, Ralis H et al. Lupus anticoagulant in patients with peripheral vascular disease: a prospective study. Eur. J. Vasc. Endovasc. Surg.9, 277–283 (1995).
   Google Scholar
• Vig S, Chitolie A, Bevan D, Dormandy J, Thompson MM, Halliday A. The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. Br. J. Surg.93, 577–581 (2006).
   PubMedGoogle Scholar
• Franck M, Staub HL, Petracco JB et al. Autoantibodies to the atheroma component β2-glycoprotein I and risk of symptomatic peripheral artery disease. Angiology58, 295–302 (2007).
   PubMedGoogle Scholar
• Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of β2-GPI. J. Autoimmun.27, 266–271 (2006).
   PubMedGoogle Scholar
• Levy PJ, Cooper CF, Gonzalez MF. Massive lower extremity arterial thrombosis and acute hepatic insufficiency in a young adult with premature atherosclerosis associated with hyperlipoproteinaemia and antiphospholipid syndrome. Angiology46, 853–858 (1995).
   PubMedGoogle Scholar
• Spronk PE, Overbosch EH, Schut NH. Severe atherosclerotic changes, including aortic occlusion, associated with hyperhomocysteinaemia and antiphospholipid antibodies. Ann. Rheum. Dis.60, 699–701 (2001).
   PubMedGoogle Scholar
• Heiss G, Sharret AR, Barnes R et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am. J. Epidemiol.134, 250–256 (1991).
   PubMed Web of Science ®Google Scholar
• Bilora F, Boccioletti V, Girolami B et al. Are antiphospholipid antibodies an independent risk factor for atherosclerosis? Clin. Appl. Thromb. Hemost8, 103–113 (2002).
   PubMedGoogle Scholar
• Jimenez S, Garcia-Criado MA, Tassies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology44, 756–761 (2005).
   PubMedGoogle Scholar
• Medina G, Casaos D, Jara LJ et al. Increased carotid artery intima–media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann. Rheum. Dis.62, 607–610 (2003).
   PubMed Web of Science ®Google Scholar
• Der H, Kerekes G, Veres K et al. Impaired endothelial function and increased carotid intima–media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome. Lupus16, 497–503 (2007).
   PubMed Web of Science ®Google Scholar
• Margarita A, Batuca J, Scenna J et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann. NY Acad. Sci.1108, 475–480 (2007).
   PubMedGoogle Scholar
• Sangle S, D’Cruz D, Jan W et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann. Rheum. Dis.62, 999–1002 (2003).
   PubMed Web of Science ®Google Scholar
• Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA. Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol.18, 931–936 (1991).
   PubMedGoogle Scholar
• Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke36, 592–596 (2005).
   PubMedGoogle Scholar
• Turiel M, Muzzupappa S, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus9, 406–412 (2000).
   PubMed Web of Science ®Google Scholar
• Turiel M, Sarzi-Puttini P, Peretti R et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am. J. Cardiol.96, 574–579 (2005).
   PubMedGoogle Scholar
• Krause I, Lev S, Fraser A et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann. Rheum. Dis.64, 1490–1493 (2005).
   PubMed Web of Science ®Google Scholar
• Berkun Y, Elami A, Meir K, Mevorach D, Naparstek Y. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J. Thorac. Cardiovasc.127, 414–420 (2004).
   PubMedGoogle Scholar
• Baron MA, Khamashta MA, Hughes GRV, D’Cruz DP. Prevalence of an abnormal ankle–brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann. Rheum. Dis.64, 144–146 (2005).
   PubMedGoogle Scholar
• Stalc M, Poredoš P, Peternel P, Tomšic M, Šebeštjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb. Res.118, 455–461 (2006).
   PubMed Web of Science ®Google Scholar
• Mercanoglu F, Erdogan D, Oflaz H et al. Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int. J. Clin. Pract.58, 1003–1007 (2004).
   PubMedGoogle Scholar
• Meroni PL, Borghi MO, Raschi E et al. Inflammatory response and the endothelium. Thromb. Res.114, 329–334 (2004).
   PubMed Web of Science ®Google Scholar
• Reitblat T, Polishchuk I, Zamir D, Isakov I, Oren S. Arterial compliance: is it reduced in antiphospholipid syndrome? J. Hum. Hypertens.20, 504–509 (2006).
   PubMedGoogle Scholar
• Vaz JLP, Dancour MAA, Bottino DA, Bouskela E. Nailfold videocapillaroscopy in primary antiphospholipid syndrome (PAPS). Rheumatology43, 1025–1027 (2004).
   PubMedGoogle Scholar
• Hughson MD, McCarty GA, Brumback RA. Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum. Pathol.26, 716–724 (1995).
   PubMed Web of Science ®Google Scholar
• Patel YI, St John A, McHugh NJ. Antiphospholipid syndrome with proliferative vasculopathy and bowel infarction. Rheumatology39, 108–110 (2000).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Sangle S, D’Cruz DP. Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome. Rheumatology46, 907–910 (2007).
   PubMedGoogle Scholar
• Afek A, Shoenfeld Y, Manor R et al. Increased endothelial cell expression of α3β1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus8, 502–507 (1999).
   PubMedGoogle Scholar
• Matsuyama K, Ueda Y, Ogino H et al. Aortic valve replacement for aortic regurgitation in a patient with primary antiphospholipid syndrome. Jpn Circ. J.63(9), 725–726 (1999).
   PubMedGoogle Scholar
• Suguta M, Hoshino Y, Naito S. Novel expression of VCAM-1 on the mitral valve in a patient with primary antiphospholipid. Heart84(5), e10 (2000).
   PubMedGoogle Scholar
• Mottram PM, Gelman JS. Mitral valve thrombus mimicking a primary tumor in the antiphospholipid syndrome. J. Am. Soc. Echocardiogr.15, 746–748 (2002).
   PubMedGoogle Scholar
• George J, Afek A, Gilburd B et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus6, 723–729 (1997).
   PubMed Web of Science ®Google Scholar
• George J, Afek A, Gilburd B et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation98, 1108–1115 (1998).
   PubMed Web of Science ®Google Scholar
• George J, Harats D, Gilburd B et al., Adoptive transfer of β(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation102, 1822–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am. Heart Hosp. J.5, 91–96 (2007).
   PubMedGoogle Scholar
• Ames PR, Tommasino C, Iannaccone L, Brillante M, Cimino R, Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies – a crucial role for acquired free protein S deficiency. Thromb. Haemost76, 190–194 (1996).
   PubMedGoogle Scholar
• Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. Anti-β2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb. Haemost.79, 42–45 (1998).
   PubMed Web of Science ®Google Scholar
• Ames PR, Pyke S, Iannaccone L, Brancaccio V. Antiphospholipid antibodies, haemostatic variables and thrombosis – a survey of 144 patients. Thromb. Haemost.73, 768–773 (1995).
   PubMedGoogle Scholar
• Ames PR, Tommasino C, D’Andrea G, Iannaccone L, Brancaccio V, Margaglione M. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies – prevalence and significance. Thromb. Haemost.79, 46–49 (1998).
   PubMed Web of Science ®Google Scholar
• Kannel WB. Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids40, 1215–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Ames PRJ, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine levels independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus11, 208–214 (2002).
   PubMed Web of Science ®Google Scholar
• Ames PRJ, Iannaccone L, Delgado Alves J, Margarita A, Brancaccio V. Factor XIII in primary antiphospholipid syndrome. J. Rheumatol.32, 1058–1062 (2005).
   PubMedGoogle Scholar
• Ames PR, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. Oxidative stress in primary antiphospholipid syndrome. Thromb. Haemost.79, 447–449 (1998).
   PubMed Web of Science ®Google Scholar
• Atsumi T, Khamashta MA, Haworth RS et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum.41, 800–807 (1998).
   PubMedGoogle Scholar
• Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation109(23 Suppl. 1), III27–III32 (2004).
   PubMed Web of Science ®Google Scholar
• Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immuno localization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol.17, 1233–1238 (1997).
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis104, 129–135 (1993).
   PubMed Web of Science ®Google Scholar
• Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br. J. Pharmacol122, 265–268 (1997).
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett.286, 152–154 (1991).
   PubMed Web of Science ®Google Scholar
• Nourooz-Zadeh J, Cooper MB, Ziegler D, Betteridge DJ. Urinary 8-epi-PGF2α and its endogenous β-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem. Biophys. Res. Commun.330, 731–736 (2005).
   PubMed Web of Science ®Google Scholar
• Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: the end of the road for antioxidant vitamin treatment? Cardiovasc. Drugs Ther.21, 195–210 (2007).
   PubMed Web of Science ®Google Scholar
• Gloire G, Legrand-Poels S, Piette J. NF-κB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol.72, 1493–1505 (2006).
   PubMed Web of Science ®Google Scholar
• Papa ND, Raschi E, Moroni G et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype In vitro. Lupus8, 423–429 (1999).
   PubMedGoogle Scholar
• Kaplanski G, Cacoub P, Farnarier C et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum.43, 55–64 (2000).
   PubMedGoogle Scholar
• Delgado Alves J, Ames PR, Donohue S et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum.46, 2686–2694 (2002).
   PubMedGoogle Scholar
• Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br. J. Haematol.114, 845–851 (2001).
   PubMedGoogle Scholar
• Yura T, Fukunaga M, Khan R, Nassar GN, Badr KF, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int.56, 471–478 (1999).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med.340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Fong LG, Parthasarathy S, Witztum JL et al. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J. Lipid Res.28, 1466–1477 (1987).
   PubMed Web of Science ®Google Scholar
• Esterbauer H, Jurgens G, Quehenberger O, et al. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res.28, 495–509 (1987).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidized LDL forms complexes with 2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res.44, 716–726 (2003).
   PubMed Web of Science ®Google Scholar
• Hasunuma Y, Matsuura E, Makita Z et al. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol.107, 569–573 (1997).
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Matsuura E, Liu Q et al. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res.42, 697–709 (2001).
   PubMed Web of Science ®Google Scholar
• Merrill JT, Zhang HW, Shen C et al. Enhancement of protein S anticoagulant function by β2-glycoprotein I, a major target antigen of antiphospholipid antibodies: β2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb. Haemost.81, 748–757 (1999).
   PubMedGoogle Scholar
• Balasubramanian K, Maiti SN, Schroit AJ. Recruitment of β-2-glycoprotein 1 to cell surfaces in extrinsic and intrinsic apoptosis. Apoptosis10, 439–446 (2005).
   PubMedGoogle Scholar
• Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. Curr. Atheroscler. Rep.8, 55–61 (2006).
   PubMedGoogle Scholar
• Ames PRJ, Delgado Alves J, Lopez LR et al. Antibodies against β2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin. Dev. Immunol.13, 1–9 (2006).
   PubMedGoogle Scholar
• Brown MS, Goldstein JL. Scavenger cell receptor shared. Nature316, 680–681 (1985).
   PubMedGoogle Scholar
• Yamamoto T, Davis CG, Brown MS et al. The human LDL receptor: a cysteine -rich protein with multiple Alu sequences in its mRNA. Cell39, 27–38 (1984).
   PubMed Web of Science ®Google Scholar
• Ramprasad MP, Fischer W, Witztum JL et al. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl Acad. Sci. USA92, 9580–9584 (1995).
   PubMedGoogle Scholar
• Rigotti A, Acton SL, Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem.270, 16221–16224 (1995).
   PubMed Web of Science ®Google Scholar
• Lopez-Pedrera C, Buendia P, Cuadrado MJ et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum.54, 301–311 (2006).
   PubMed Web of Science ®Google Scholar
• Ferro D, Saliola M, Meroni PL et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J. Thromb. Haemost.1, 523–531 (2003).
   PubMed Web of Science ®Google Scholar
• Sorenson RC, CL Bisgaier, M Aviram et al. Human serum Paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol.19, 2214–2225 (1999).
   PubMed Web of Science ®Google Scholar
• Khuseyinova N, Koenig W. Apolipoprotein A-I and risk for cardiovascular diseases. Curr. Atheroscler. Rep.8, 365–373 (2006).
   PubMedGoogle Scholar
• Batuca JR, Ames PRJ, Isenberg DA, Delgado Alves J. Antibodies towards high density lipoproteins components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann. NY Acad. Sci.1108, 137–146 (2007).
   PubMedGoogle Scholar
• Ritis K, Doumas M, Mastellos D et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol.177, 4794–4802 (2006).
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Campoamor MT, Chamorro A et al. Hypocomplementemia in systemic lupus erythematosus and primary antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus13, 777–783 (2004).
   PubMedGoogle Scholar
• Redecha P, Tilley R, Tencati M et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood.110, 2423–2431 (2007).
   PubMed Web of Science ®Google Scholar
• Ames PRJ, Tommasino C, Brancaccio V, Ciampa A. C-reactive protein in primary antiphospholipid syndrome. J. Rheumatol.34, 650 (2007).
   PubMedGoogle Scholar
• Figueredo MA, Rodriguez A, Ruiz-Yague M et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J. Rheumatol.33, 1980–1986 (2006).
   PubMedGoogle Scholar
• Meroni PL, Raschi E, Testoni C et al. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum.44, 2870–2878 (2001).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol.28, 88–98 (2007).
   PubMed Web of Science ®Google Scholar
• Ames PRJ, Tommasino C, Alves J et al. Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study. Lupus9, 688–695 (2000).
   PubMed Web of Science ®Google Scholar
• Pratico D, Ferro D, Iuliano L et al. Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood93, 3401–3407 (1999).
   PubMed Web of Science ®Google Scholar
• Dunoyer-Geindre S, Kruithof EK, Boehlen F, Satta-Poschung N, Reber G, de Moerloose P. Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies. J. Thromb. Haemost.2, 1176–1181 (2004).
   PubMedGoogle Scholar
• Zhou H, Wolberg AS, Roubey RAS. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood104, 2353–2358 (2004).
   PubMed Web of Science ®Google Scholar
• Deguchi H, Takeya H, Wada V et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood90, 2345–2356 (1997).
   PubMed Web of Science ®Google Scholar
• Shrestha B, Hidai C, Ikeda H, Okada-ohno M, Kasanuki H, Kawana M. Endothelin-1 gene expression in endothelial cells is potently inhibited by a vasodilator, Dilazep. Hypertens. Res.27, 409–4415 (2004).
   PubMedGoogle Scholar
• Rubenstein E, Arkfeld DG, Metyas S, Shinada S, Ehresmann S, Liebman HA. Rituximab treatment for resistant antiphospholipid syndrome. J. Rheumatol.33, 355–357 (2006).
   PubMed Web of Science ®Google Scholar
• Trappe R, Loew A, Thuss-Patience P, Dorken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab – monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann. Hematol.85, 134–135 (2006).
   PubMedGoogle Scholar
• Ames PR, Tommasino C, Fossati G, Scenna G, Brancaccio V, Ferrara F. Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome. Ann. Hematol.86, 227–228 (2007).
   PubMedGoogle Scholar